The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients

Burl R Don, Kyoungmi Kim, J. Li, T. Dwyer, F. Alexander, George Kaysen

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

Background: Inflammation strongly predicts all-cause and cardiovascular mortality among dialysis patients. The negative acute-phase proteins, albumin and prealbumin are both inversely associated with mortality. Both albumin and prealbumin levels are decreased by inflammation.We carried out a pilot study to establishwhether treatmentwith the tumor necrosis factor-α receptor antagonist etanercept would be safe and result in improved levels of albumin and prealbumin in inflamed hypoalbuminemic (albumin < 3.8 g/dl, CRP > 8.0 mg/l) prevalent hemodialysis patients. Methods: We excluded patients who had infectious risk (hepatitis C or B positive, HIV positive, purified protein derivative (PPD) positive or having a history of tuberculosis, having a tunneled dialysis catheter) to find patients having both hypoalbuminemia and inflammation. Of 433 less than 6% met the inclusion criteria. 10 patients were randomized to receive etanercept or placebo twice weekly for 44 weeks. Results: There were no adverse infectious events. There was no significant difference for any of the measurements between the two groups. However there was a significant difference in the time-dependent effects of etanercept on prealbumin: increasing 20% in the etanercept group while decreasing in the placebo group. Conclusions: Administration of a TNF-α receptor antagonist appears safe in this selected population, despite the large increase in infectious risk observed in the dialysis patient population. The effect on surrogate markers of inflammation is small.

Original languageEnglish (US)
Pages (from-to)431-438
Number of pages8
JournalClinical Nephrology
Volume73
Issue number6
StatePublished - Jun 2010

Keywords

  • Albumin
  • IL-6
  • Inflammation-CRP
  • Prealbumin
  • sICAM
  • TNF-α
  • VEGF

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients'. Together they form a unique fingerprint.

  • Cite this